Boston Scientific Corporation — FY 2023 Form 10-K
Reporting period: Year ended December 31, 2023. This is an annual filing, not a standalone fourth-quarter report; the supplied filing text does not provide clear Q4-only results.
Business context
Boston Scientific develops and sells medical devices globally across two reportable segments: MedSurg and Cardiovascular. It reported sales in 140 countries; international sales represented 41% of total net sales. Its strategy emphasizes category leadership, growth adjacencies, international expansion, innovation and operational efficiency.
Financial results and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Net sales | $14.240 billion | $12.682 billion |
| GAAP operating income | $2.343 billion | $1.649 billion |
| Net income attributable to common stockholders | $1.570 billion | $642 million |
| Diluted EPS | $1.07 | $0.45 |
| Cash from operating activities | $2.503 billion | $1.526 billion |
| Cash and cash equivalents at year-end | $865 million | $928 million |
| Total debt at year-end | $9.102 billion | $8.935 billion |
Net sales rose 12.3% reported, 13.1% operational (excluding currency), and 12.3% organic (excluding currency and specified acquisition/divestiture effects). Gross margin improved to 69.5% from 68.8%. Management attributed the improvement mainly to product mix and lower manufacturing, materials and freight costs, partly offset by currency effects and period expenses.
Adjusted net income attributable to common stockholders, a non-GAAP measure, was $2.999 billion, or $2.05 per diluted share, versus $2.459 billion, or $1.71, in 2022. The company excluded $1.429 billion after tax of specified charges and credits in 2023; these adjusted results should be considered alongside, not instead of, GAAP results.
Capital expenditures and internal-use software purchases were $711 million. Investing cash outflow was $2.574 billion, including $1.811 billion of net acquisition payments. Current assets were $6.514 billion and current liabilities were $4.933 billion. The company had $2.750 billion available under its revolving credit facility, with no revolver or commercial paper borrowings outstanding. It reported covenant compliance and a 2.33x leverage ratio against a 3.75x maximum.
Material changes versus 2022
- Cardiovascular segment sales increased 12.6% to $8.819 billion; MedSurg sales increased 10.4% to $5.422 billion. Cardiology sales grew 13.1%, with growth led by WATCHMAN, electrophysiology products and coronary guidance products.
- Operating cash flow increased $977 million, supported by higher sales and operating income and lower non-recurring tax payments, partly offset by increased inventory purchases.
- Reported net income increased substantially; comparisons were affected by unusual items, including 2022 debt-extinguishment charges and larger litigation charges, and the 2023 conversion of mandatory convertible preferred stock into common shares.
- Year-end inventory rose to $2.484 billion from $1.867 billion. Total debt rose to $9.102 billion from $8.935 billion.
- 2023 acquisitions included a majority stake in Acotec, Apollo Endosurgery and Relievant Medsystems. These added products and capabilities in vascular intervention, endoscopy and neuromodulation.
Outlook, commentary and risks
- Liquidity outlook: Management said existing cash, anticipated operating cash generation, capital-market access and credit facilities should fund operations, investment, legal liabilities, debt service and possible acquisitions for the next 12 months and foreseeable future.
- Restructuring: The plan begun in 2023 is expected to be substantially complete by the end of 2025, with estimated pre-tax charges of $450–$550 million and gross annual pre-tax expense reductions of $225–$275 million as benefits are realized. Management expects to reinvest a substantial portion of savings in growth initiatives.
- Regulatory costs: EU MDR implementation expenses totaled $340 million cumulatively through year-end 2023; expected total expenses are approximately $450–$500 million.
- Subsequent acquisition: In January 2024, the company agreed to acquire Axonics for approximately $3.670 billion in cash, expected to close in the first half of 2024, subject to customary conditions. It planned to use cash and new debt. This is a post-year-end event, not a 2023 operating result.
- Key risks: Competition and pricing/reimbursement pressure; supply-chain, sterilization and labor constraints; product development, clinical and regulatory approval risk; foreign currency and geopolitical exposure; cybersecurity; acquisition integration; and potential litigation, tax or restructuring costs.
- Legal matters: Accrued legal matters were $377 million at year-end, including amounts primarily related to transvaginal mesh claims. The company is substantially self-insured for product liability and fully self-insured for intellectual-property infringement claims. It disclosed ongoing patent and product-liability matters and government inquiries, including DOJ inquiries involving its ambulatory ECG monitoring business and peripheral-intervention services through office-based labs. Outcomes and potential losses for certain matters are uncertain.
- Unusual items: 2023 included $111 million of net litigation credits, primarily related to settlement of offensive patent litigation, compared with $173 million of litigation charges in 2022. A 2023 intangible-asset impairment charge was $58 million. The filing does not provide a formal financial guidance range in the supplied text.
Important facts for investors to verify
- Reconcile reported GAAP earnings with the company’s adjusted earnings and assess the recurring nature of excluded charges and credits.
- Track whether sales growth, especially in WATCHMAN and electrophysiology, continues and translates into sustainable margins and cash flow.
- Monitor inventory growth, debt maturities, covenant headroom and the funding and leverage effects of the Axonics transaction.
- Assess restructuring execution, actual cash costs and savings, and the remaining EU MDR transition costs.
- Review developments in mesh-related claims, patent litigation and government investigations, including potential cash and operational consequences.
- Consider that management and the auditor reported effective internal control over financial reporting, but 2023 acquisitions Acotec, Apollo and Relievant were excluded from the assessment; together they represented less than 1% of total assets and approximately 1% of revenue.